Additionally, in a clinical trial of 30 individuals with refractory SLE, it was noted that cell transplantation was safe with minimal side effects and there was an increase in Treg cell account, accompanied by a consistent decrease in IL-17 levels at 3, 6, and 12 months post-treatment. The gene discussed is IL17A; the disease is systemic lupus erythematosus.